Transaction specifics
Director Tommy G Thompson executed a sale of United Therapeutics (NASDAQ: UTHR) common stock on March 26, 2026, disposing of 1,999 shares for a total that equates to approximately $1.1 million. The price per share in the reported sale ranged from $537.6192 to $540.175.
Concurrent option exercise
On the same date, Thompson exercised stock options to buy 2,000 shares of United Therapeutics common stock at an exercise price of $101.80 per share, for an aggregate purchase value of $203,600.
Market context
United Therapeutics shares have traded near a 52-week high of $549.50 and have recorded a 74% increase over the prior 12-month period. Separately, InvestingPro analysis noted that the stock currently appears slightly overvalued relative to its Fair Value and that 14 additional ProTips are available to subscribers.
Corporate capital actions and analyst response
The company recently announced a $2 billion stock repurchase program. That program includes an initial $1.5 billion accelerated share repurchase agreement with Citibank and a further $500 million that the company may deploy for additional repurchases at its discretion. The announcement prompted reaffirmations and updates from equity analysts: TD Cowen reiterated a Buy rating with a $575 price target, while Cantor Fitzgerald raised its price target to $625 and maintained an Overweight rating, citing expectations tied to the company’s TETON-1 trial in its outlook.
Clinical data
Adding to the company’s recent newsflow, the New England Journal of Medicine published results from United Therapeutics’ phase 3 TETON-2 study evaluating nebulized Tyvaso for idiopathic pulmonary fibrosis. The study met its primary endpoint, demonstrating a statistically significant improvement in lung function versus placebo over a 52-week period.
What this collection of events indicates
The insider sale and option exercise occurred against a backdrop of strong share price performance, a substantial share repurchase authorization, analyst optimism on upcoming trial readouts, and positive Phase 3 data publication. Together these facts outline the current factual landscape without drawing causal links beyond the reported actions and disclosures.
Note: All transaction figures, analyst ratings, trial results, and program sizes are reported as disclosed; no additional extrapolation is made.